Европейски съюз - български - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - доксорубицин хидрохлорид - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Антинеопластични средства - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

България - български - Изпълнителна агенция по лекарствата

yes pharmaceutical development services gmbh - Ацетат на натрий, натриев хлорид, калиев хлорид, Поли(0-2-гидроксиэтил) нишесте, калциев хлорид, ябълчна киселина - 100 mg/ml solution for infusion

Европейски съюз - български - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Антинеопластични средства - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Европейски съюз - български - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Офталмологични - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

България - български - Изпълнителна агенция по лекарствата

bayer pharma ag - 0,02 mg/3 mg film - coated tablets

България - български - Изпълнителна агенция по лекарствата

Месер България ЕООД - 100 % v/v medicinal gas, liquefied

България - български - Изпълнителна агенция по лекарствата

200 micrograms compressed lozenges with integral oromucosal applicator

България - български - Изпълнителна агенция по лекарствата

400 micrograms compressed lozenges with integral oromucosal applicator

България - български - Изпълнителна агенция по лекарствата

600 micrograms compressed lozenges with integral oromucosal applicator

България - български - Изпълнителна агенция по лекарствата

800 micrograms compressed lozenges with integral oromucosal applicator